Compositions and methods for the treatment of immune related...

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C536S023500, C424S185100, C435S320100, C435S252330, C435S254200, C435S358000, C530S350000

Reexamination Certificate

active

07419799

ABSTRACT:
The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.

REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 2003/0092017 (2003-05-01), Finger
patent: 2004/0005317 (2004-01-01), Dedera et al.
patent: 2005/0027114 (2005-02-01), Kuo et al.
patent: 2005/0260714 (2005-11-01), Agarwal et al.
patent: WO 01/55336 (2001-08-01), None
Bottino et al., J. Exp. Med. 2001, vol. 193(3), pp. 235-246.
Parolini, et al., X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. Aug. 7, 2000;192(3):337-46.
Miyata et al., Nucleotide sequence divergence and functional constraint in mRNA evolution. Proc Natl Acad Sci U S A. Dec. 1980;77(12):7328-32.
Bowie, et al., Deciphering the message in protein sequences: tolerance to amino acid substitutions.Science. Mar. 16, 1990;247(4948):1306-10.
Wells et al., Additivity of mutational effects in proteins. Biochemistry. Sep. 18, 1990;29(37):8509-17.
Benjamin et al. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the performed endothelial network and is regulated by PDGF-B and VEGF. Development. May 1998; 125(9):1591-8.
Vukicevic et al. Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenic protein 7). PNAS USA. Aug. 20, 1996; 93:9021-6.
Brenner. Errors in genome annotation. Trends Genet. Apr. 1999;15(4):132-3.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. Jan. 2000;18(1)34-9.
Bork P. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Research. Apr. 2000; 10(4):398-400.
Doerks et al. Protein annotation: detective work for function prediction. Trends Genet. Jun. 1998; 14(6):248-50.
Bork et al. Go hunting in sequence databases but watch out for the traps. Trends Genet. Oct. 1996; 12(10):425-7.
Aversa et al., “Engagement of the Signaling Lymphocytic Activation Molecule (SLAM) on Activated T Cells Results in IL-2 Independent, Cyclosporin A Sensitive T Cell Proliferation and IFN-γ Production.”J. Immunol. 158(9) : 4036-4044 (1997).
Aversa et al., “SLAM and its Role in T Cell Activation and Th Cell Responses.”Immunol. Cell. Bio. 75 (2) : 202-205 (1997).
Carreno and Collins., “The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Responses.”Ann. Rev. Immunol. 20 : 29-53 (2002).
Castro et al., “Molecular and Functional Characterization of Mouse Signaling Lymptocytic Activation Molecule (SLAM) : Differential Expression and Responsiveness in Th1 and Th2 Cells.” J.Immunol. 163 (11) : 5860-5870 (1999).
Cocks et al., “A Novel Receptor Involved in T-Cell Activation.”Nature. 376 (6537) : 260-263 (Jul. 1995).
Gell and Coombs, eds.Clinical Aspects of Immunology., second edition. Oxford:Blackwell Scientific Publications (1968).
Howie et al., “Molecular Dissection of the Signaling and Costimulatory Functions of CD150 (SLAM) : CD150/SAP Binding and CD150-Mediated Costimulation.”Blood. 99 (3) : 957-965 (2002).
Latour et al., “Regulation of SLAM-Mediated Signal Transduction by SAP, the X-Linked Lymphoproliferative Gene Product.”Nature Immunology, 2 (8) : 681-690 (Aug. 2001).
Lewis et al., “Distinct Interactions of the X-Linked Lymphoproliferative Syndrome Gene Product SAP with Cytoplasmic Domains of Members of the CD2 Receptor Family.”Clin. Immunol. 100 (1) : 15-23 (2001).
Mavaddat et al., “Signaling Lymphocytic Activation Molecule (CDw150) is Homophilic but Self-Associates with Very Low Affinity.”J. Bio. Chem. 275 (36) : 28100-28109 (2000).
Morra et al., “Characterization of SH2D1A Missorise Mutations Identified in X-Linked Lymphoproliferative Disease Patients.”J. Bio. Chem. 276 (39) : 36809-36816 (2001).
Nichols et al., 'SAP: Natural Inhibitor or Grand SLAM of T Cell Activation?Nature Immunology. 2 (8) : 665 666 (Aug. 2001).
Rich and Myszka., “Advances in Surface Plasmon Resonance Biosensor Analysis.”Curr. Opin, Biotech, 11:54-61 (2000).
Shlapatska et al., “CD150 Association with Either the SH2-Containing Inositol Phosphatase or the SH2-Containing Protein Tyrosine Phosphatase is Regulated by the Adaptor Protein SH2D1A.”J. Immunol. 166 (9) : 5480-5487 (2001).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Compositions and methods for the treatment of immune related... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for the treatment of immune related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of immune related... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3984095

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.